Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2246 in Adult Participants With Motor Dysfunction Associated With Ischemic Stroke
NCT07318714Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2026
- Primary completion
- Feb 2030
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ASP2246 in ischemic stroke (3 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-Limiting Toxicity up to 2 Weeks, Treatment-Emergent Adverse Events up to 52 Weeks and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
ASP2246
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07318714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318714.